Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | tar DNA-binding protein | 0.0064 | 0.1637 | 0.1637 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0024 | 0.0173 | 0.5 |
Schistosoma mansoni | myelin transcription factor 1 myt1 | 0.0055 | 0.1303 | 0.1303 |
Onchocerca volvulus | 0.0153 | 0.4875 | 1 | |
Echinococcus granulosus | arachidonate 5 lipoxygenase | 0.0115 | 0.3492 | 0.4351 |
Loa Loa (eye worm) | hypothetical protein | 0.0055 | 0.1303 | 0.1623 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0027 | 0.0285 | 0.0356 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0027 | 0.0285 | 0.5 |
Onchocerca volvulus | 0.0048 | 0.1059 | 0.2173 | |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0027 | 0.0285 | 0.0356 |
Leishmania major | p450 reductase, putative | 0.0027 | 0.0285 | 1 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0027 | 0.0285 | 0.0356 |
Echinococcus multilocularis | survival motor neuron protein 1 | 0.024 | 0.8026 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0172 | 0.5552 | 0.5552 |
Echinococcus granulosus | suppression of tumorigenicity 18 protein | 0.0055 | 0.1303 | 0.1623 |
Plasmodium vivax | unspecified product | 0.0112 | 0.3382 | 1 |
Echinococcus multilocularis | endonuclease exonuclease phosphatase | 0.0191 | 0.6236 | 0.777 |
Brugia malayi | hypothetical protein | 0.0153 | 0.4875 | 0.6075 |
Brugia malayi | RNA binding protein | 0.0064 | 0.1637 | 0.2039 |
Brugia malayi | C2-HC type zinc finger protein C.e-MyT1 | 0.0055 | 0.1303 | 0.1623 |
Schistosoma mansoni | tar DNA-binding protein | 0.0064 | 0.1637 | 0.1637 |
Trypanosoma cruzi | p450 reductase, putative | 0.0027 | 0.0285 | 0.5 |
Echinococcus multilocularis | tar DNA binding protein | 0.0064 | 0.1637 | 0.2039 |
Echinococcus granulosus | polycomb protein SCMH1 | 0.0048 | 0.1059 | 0.132 |
Loa Loa (eye worm) | mbt repeat family protein | 0.0048 | 0.1059 | 0.132 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0027 | 0.0285 | 0.5 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0027 | 0.0285 | 0.5 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0027 | 0.0285 | 1 |
Loa Loa (eye worm) | TAR-binding protein | 0.0064 | 0.1637 | 0.2039 |
Schistosoma mansoni | hypothetical protein | 0.0049 | 0.1079 | 0.1079 |
Onchocerca volvulus | Polycomb protein Sfmbt homolog | 0.0048 | 0.1059 | 0.2173 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0027 | 0.0285 | 0.5 |
Echinococcus multilocularis | arachidonate 5 lipoxygenase | 0.0115 | 0.3492 | 0.4351 |
Plasmodium vivax | vivapain-1 | 0.0112 | 0.3382 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0027 | 0.0285 | 0.0356 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0064 | 0.1637 | 0.2039 |
Schistosoma mansoni | tar DNA-binding protein | 0.0064 | 0.1637 | 0.1637 |
Schistosoma mansoni | sex comb on midleg homolog | 0.0048 | 0.1059 | 0.1059 |
Schistosoma mansoni | tar DNA-binding protein | 0.0064 | 0.1637 | 0.1637 |
Schistosoma mansoni | lipoxygenase | 0.0081 | 0.223 | 0.223 |
Echinococcus granulosus | geminin | 0.0172 | 0.5552 | 0.6918 |
Brugia malayi | FAD binding domain containing protein | 0.0027 | 0.0285 | 0.0356 |
Echinococcus granulosus | tar DNA binding protein | 0.0064 | 0.1637 | 0.2039 |
Loa Loa (eye worm) | hypothetical protein | 0.0153 | 0.4875 | 0.6075 |
Schistosoma mansoni | lipoxygenase | 0.0115 | 0.3492 | 0.3492 |
Echinococcus granulosus | survival motor neuron protein 1 | 0.024 | 0.8026 | 1 |
Schistosoma mansoni | scm-relatedprotein containing 4 mbt domains (sfmbt) | 0.0048 | 0.1059 | 0.1059 |
Echinococcus granulosus | endonuclease exonuclease phosphatase | 0.0191 | 0.6236 | 0.777 |
Brugia malayi | mbt repeat family protein | 0.0048 | 0.1059 | 0.132 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0027 | 0.0285 | 0.0844 |
Loa Loa (eye worm) | hypothetical protein | 0.0048 | 0.1059 | 0.132 |
Echinococcus granulosus | SAM and MBT domain containing protein | 0.0048 | 0.1059 | 0.132 |
Echinococcus granulosus | histone acetyltransferase MYST2 | 0.0055 | 0.1303 | 0.1623 |
Echinococcus multilocularis | SAM and MBT domain containing protein | 0.0048 | 0.1059 | 0.132 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0027 | 0.0285 | 0.0356 |
Echinococcus multilocularis | suppression of tumorigenicity 18 protein | 0.0055 | 0.1303 | 0.1623 |
Loa Loa (eye worm) | hypothetical protein | 0.024 | 0.8026 | 1 |
Giardia lamblia | Hypothetical protein | 0.0024 | 0.0173 | 0.5 |
Echinococcus multilocularis | polycomb protein SCMH1 | 0.0048 | 0.1059 | 0.132 |
Plasmodium falciparum | cysteine proteinase falcipain 1 | 0.0112 | 0.3382 | 1 |
Echinococcus multilocularis | histone acetyltransferase MYST2 | 0.0055 | 0.1303 | 0.1623 |
Schistosoma mansoni | sex comb on midleg homolog | 0.0048 | 0.1059 | 0.1059 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0064 | 0.1637 | 0.2039 |
Loa Loa (eye worm) | MBCTL1 | 0.0055 | 0.1303 | 0.1623 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0027 | 0.0285 | 0.0285 |
Plasmodium vivax | unspecified product | 0.0105 | 0.3111 | 0.9198 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0027 | 0.0285 | 0.5 |
Echinococcus multilocularis | geminin | 0.0172 | 0.5552 | 0.6918 |
Brugia malayi | TAR-binding protein | 0.0064 | 0.1637 | 0.2039 |
Brugia malayi | mbt repeat family protein | 0.0048 | 0.1059 | 0.132 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0027 | 0.0285 | 0.5 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0027 | 0.0285 | 1 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0027 | 0.0285 | 0.0356 |
Plasmodium vivax | flavodoxin domain containing protein | 0.0024 | 0.0173 | 0.0512 |
Brugia malayi | flavodoxin family protein | 0.0027 | 0.0285 | 0.0356 |
Schistosoma mansoni | survival motor neuron protein | 0.0049 | 0.1079 | 0.1079 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0027 | 0.0285 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0027 | 0.0285 | 0.5 |
Onchocerca volvulus | 0.0049 | 0.1079 | 0.2213 | |
Schistosoma mansoni | tar DNA-binding protein | 0.0064 | 0.1637 | 0.1637 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0027 | 0.0285 | 0.0844 |
Schistosoma mansoni | hypothetical protein | 0.0172 | 0.5552 | 0.5552 |
Brugia malayi | hypothetical protein | 0.024 | 0.8026 | 1 |
Brugia malayi | Iron-sulfur cluster assembly accessory protein | 0.0049 | 0.1079 | 0.1344 |
Loa Loa (eye worm) | RNA binding protein | 0.0064 | 0.1637 | 0.2039 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
APTT (functional) | No activity 0 s | Anticoagulantactivity of compound in respect to APTT in human poor platelet plasma (PPP) at a concentration 41.89(nM) of was measured by the Amelung coagulometer KC4A apparatus | ChEMBL. | 16084083 |
APTT (functional) | = 3.8 s | Anticoagulantactivity of compound in respect to APTT in human poor platelet plasma (PPP) at a concentration 272.29(nM) of was measured by the Amelung coagulometer KC4A apparatus | ChEMBL. | 16084083 |
APTT (functional) | = 5.5 s | Anticoagulantactivity of compound in respect to APTT in human poor platelet plasma (PPP) at 418.91 nM concentration was measured by the Amelung coagulometer KC4A apparatus | ChEMBL. | 16084083 |
APTT (functional) | = 15.6 s | Anticoagulantactivity of compound in respect to APTT in human poor platelet plasma (PPP) at a concentration 523.64(nM) of was measured by the Amelung coagulometer KC4A apparatus | ChEMBL. | 16084083 |
APTT (functional) | = 62.4 s | Anticoagulantactivity of compound in respect to APTT in human poor platelet plasma (PPP) at a concentration 802.24(nM) of was measured by the Amelung coagulometer KC4A apparatus | ChEMBL. | 16084083 |
IC50 (functional) | = 802.240000000001 nM | Concentration of the compound for doublingAPTT clotting times of human plasma | ChEMBL. | 16084083 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.